Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 09 May 2025
A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available ...
Read Full NewsA new study will follow adults with chronic inflammatory demyelinating polyradiculoneuropathy who start subcutaneous efgartigimod in routine practice in the US and Germany.
The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]
Findings from the phase 1/2 RESET-MG trial, presented at AANEM 2026, showed that 10 of 13 patients with refractory generalized myasthenia gravis had clinically meaningful MG-ADL improvements after a single infusion of rese-cel.
In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.
In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.
1.
New BCMA-Directed Therapies Show Promise in Multiple Myeloma
2.
Enhanced CAR T cell therapy offers new strategy for lymphoma
3.
Antibiotic Stewardship: Five Tips to Reduce Resistance
4.
A computer-aided diagnostic system for improved detection of breast cancer.
5.
New Gene Therapy Nears EU Nod for Bladder Cancer
1.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
2.
Ticagrelor Monotherapy vs. Ticagrelor + Aspirin in ACS Post-PCI: ULTIMATE-DAPT Trial
3.
Bone Marrow Niche Regeneration Through Microenvironment Engineering
4.
Disturbed Red-Cell Production Dynamics During Chronic Marrow Stress
5.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Updates on the First Line Management of ALK+ NSCLC
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
4.
Understanding the Importance of Follow-Up After Cancer Treatment
5.
The Role of Platelets in Normal Blood Clotting
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge